GlassScriptPhysician profile
Jared Grodman
NPI 1013404540
$7,038.08
in general payments reported to CMS, 2019-2025
35 companies · $2,277 in 2025
The $2,277 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $517 · 2021: $361 · 2022: $575 · 2023: $1,132 · 2024: $1,783 · 2025: $2,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,993 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,992.99 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,600.07 | 2022-2025 | |
| Janssen Biotech, INC. | $863.41 | 2022-2025 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $393.49 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $362.50 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $275.74 | 2022-2025 | |
| Gilead Sciences, INC. | $273.67 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.88 | 2019-2025 | Xifaxan, Plenvu |
| Ardelyx, INC. | $242.79 | 2023-2025 | Ibsrela |
| Vifor Pharma, INC. | $238.18 | 2019-2020 | |
| Amgen INC. | $231.41 | 2020-2021 | |
| Qol Medical, LLC | $220.55 | 2022-2025 | Sucraid |
| E.R. Squibb & Sons, L.L.C. | $217.34 | 2019-2021 | |
| Pfizer INC. | $179.17 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.33 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Novo Nordisk INC | $165.19 | 2021-2025 | Wegovy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $161.70 | 2022-2023 | Exalt Model D |
| Medtronic, INC. | $128.90 | 2023 | Gi Genius |
| Ironwood Pharmaceuticals, INC | $127.84 | 2023-2024 | Linzess |
| Lilly USA, LLC | $122.73 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $121.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $104.67 | 2024-2025 | |
| Evoke Pharma, INC. | $103.45 | 2023 | Gimoti |
| Exact Sciences Corporation | $86.31 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $86.27 | 2019-2023 | Dificid |
| Aimmune Therapeutics, INC. | $70.35 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $50.83 | 2024-2025 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $36.88 | 2025 | Iqirvo |
| Sandoz INC. | $23.87 | 2024 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $21.08 | 2023 | |
| Amarin Pharma, INC. | $18.25 | 2020 | |
| Celltrion USA INC. | $16.53 | 2025 | Vegzelma |
| Shield Therapeutics INC | $16.26 | 2025 | |
| Vivus LLC | $15.11 | 2025 | Qsymia |
| Redhill Biopharma INC. | $13.63 | 2022 | |
| Irhythm Technologies, INC. | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Grodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.